<PAGE>
FORM 10-K/A
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT TO APPLICATION OR REPORT
FILED PURSUANT TO SECTION 12, 13, OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
DEKALB Genetics Corporation
-------------------------------------------------
(Exact name of registrant as specified in charter)
AMENDMENT NO. 1
The undersigned registrant hereby amends the following items, financial
statements, exhibits or other portions of its Annual Report for 1995 on Form 10-
K as set forth in the pages attached hereto:
Exhibit 27 - Financial Data Statement
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this amendment to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date: November 16, 1995
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
DEKALB GENETICS CORPORATION
Date: October 10, 1995 By: Bruce P. Bickner
-------------------------------
Bruce P. Bickner
Chairman, Chief Executive Officer
and Director
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities on this 12th day of October, 1995.
Signature Title
--------- -----
Richard O. Ryan President, Chief Operating Officer
---------------
Richard O. Ryan and Director
Thomas R. Rauman Vice President - Finance and
----------------
Thomas R. Rauman Chief Financial Officer
DIRECTORS
---------
Charles J. Arntzen Allan Aves
------------------ ----------
Charles J. Arntzen Allan Aves
Tod R. Hamachek Paul H. Hatfield
--------------- ----------------
Tod R. Hamachek Paul H. Hatfield
Douglas C. Roberts John T. Roberts
------------------ ---------------
Douglas C. Roberts John T. Roberts
H. Blair White
--------------
H. Blair White
[ARTICLE] 5
<PAGE>
This schedule contains summary financial information extracted from the
Consolidated Statement of Operations and the Consolidated Balance Sheets and is
qualified in its entirety by reference to such financial statements
<TABLE>
<S> <C>
[PERIOD-TYPE] YEAR
[FISCAL-YEAR-END] AUG-31-1995
[PERIOD-END] AUG-31-1995
[CASH] 3000
[SECURITIES] 0
[RECEIVABLES] 60300
[ALLOWANCES] 2700
[INVENTORY] 100800
[CURRENT-ASSETS] 175000
[PP&E] 240000
[DEPRECIATION] 140200
[TOTAL-ASSETS] 323000
[CURRENT-LIABILITIES] 94600
[BONDS] 0
[COMMON] 500
[PREFERRED-MANDATORY] 0
[PREFERRED] 0
[OTHER-SE] 125800
[TOTAL-LIABILITY-AND-EQUITY] 323000
[SALES] 309500
[TOTAL-REVENUES] 319400
[CGS] 162300
[TOTAL-COSTS] 64500
[OTHER-EXPENSES] 67000
[LOSS-PROVISION] 600
[INTEREST-EXPENSE] 8500
[INCOME-PRETAX] 15100
[INCOME-TAX] 5600
[INCOME-CONTINUING] 9500
[DISCONTINUED] 1200
[EXTRAORDINARY] 0
[CHANGES] 0
[NET-INCOME] 10700
[EPS-PRIMARY] 2.04
[EPS-DILUTED] 0
</TABLE>
